新医学2012，Vol.43Issue(5)：281-284,4.DOI:10.3969/g.issn.0253-9802.2012.05.001
骨髓增殖性肿瘤分子靶向治疗策略
The progress of molecular targeted therapy of myeloproliferative neoplasm
摘要
Abstract
Myeloproliferative neoplasms (MPN) are characterized by the abnormal proliferation of one or more myeloid cell lines. The activating tyrosine kinase mutation JAK2V617F may play a key role in the molecular patho-genesis of certain types of MPN. The discovery has greatly promoted the development of JAK2-selective inhibitors for the treatment of MPN. This review summarizes the status of JAK2 inhibitors in targeted therapy of MPN and discusses their benefits and challenges.关键词
骨髓增殖性肿瘤/JAK2V617F/靶向治疗Key words
Myeloproliferative neoplasm / JAK2V617F/ Targeted therapy引用本文复制引用
任媛媛,张凌岩,李英..骨髓增殖性肿瘤分子靶向治疗策略 [J].新医学,2012,43(5):281-284,4.基金项目
山东省自然科学基金(Y2007C059) （Y2007C059）
